Renal Failure News and Research RSS Feed - Renal Failure News and Research

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.
Scientists trace one of the causes of ischemia renal failure

Scientists trace one of the causes of ischemia renal failure

Every year acute renal failure affects over 13 million people and leads to 1.7 million deaths across the globe. It often develops when an insufficient supply of oxygen reaches the kidneys, a condition called ischemia. [More]
ISHLT issues new list of criteria to determine patient eligibility for heart transplant

ISHLT issues new list of criteria to determine patient eligibility for heart transplant

To determine patient eligibility for heart transplant, the International Society for Heart Lung Transplantation maintains a list of criteria, first issued in 2006, that acts as a guideline for physicians. [More]
CTA scans with reduced amount of contrast medium and radiation dose still provide good image quality

CTA scans with reduced amount of contrast medium and radiation dose still provide good image quality

Wouter Nijhof obtained his PhD at the University of Twente for the research he conducted in collaboration with the Radiology department at the Jeroen Bosch Hospital in 's-Hertogenbosch. [More]
Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approved to reduce the production of uric acid in the body. [More]
Shingles vaccine can help protect elderly patients with end-stage renal disease

Shingles vaccine can help protect elderly patients with end-stage renal disease

Elderly patients with end-stage renal disease (ESRD) who received the shingles vaccine were half as likely to develop shingles compared to those who were not vaccinated. The new study from Kaiser Permanente, published in Clinical Infectious Diseases, also found the best protection against shingles was achieved when patients received the vaccination shortly after beginning dialysis. [More]
Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company. [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Plasmacytoid dendritic cells may not contribute to late-stage lupus

Plasmacytoid dendritic cells may not contribute to late-stage lupus

For years, biomedical researchers have suspected that a specific set of immune cells are responsible for causing disease in lupus patients, but until now they haven't known for sure one way or the other. [More]
Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma. [More]
Testosterone treatment can benefit men with Type 2 diabetes

Testosterone treatment can benefit men with Type 2 diabetes

Men with Type 2 diabetes who have low testosterone levels can benefit significantly from testosterone treatment. [More]
European and North American blood pressure guidelines may increase stroke risk in older Asian patients

European and North American blood pressure guidelines may increase stroke risk in older Asian patients

European and North American blood pressure guidelines, issued last year, may actually boost the stroke risk if used for Asian patients, particularly the elderly, suggests an expert opinion published online in the journal Heart Asia. [More]
RPCI-led researchers identify strategies to prevent acute kidney injury

RPCI-led researchers identify strategies to prevent acute kidney injury

Acute kidney injury (AKI), also known as acute renal failure, is one of the main contributors to death and disability worldwide, yet no preventive treatment for the condition has been established. In a new study published in the journal Cell Death and Differentiation, a team of researchers led by scientists from Roswell Park Cancer Institute reports that they have identified 10 genes whose inhibition appears to protect kidney cells. [More]
New collaboration aims to develop novel generation artificial pancreas

New collaboration aims to develop novel generation artificial pancreas

Debiotech SA, the ARTORG Center for Biomedical Engineering Research of the University of Bern - and the Division of Endocrinology, Diabetes and Clinical Nutrition of the Bern University Hospital "Inselspital" are proud to announce the start of an exclusive collaboration to develop a novel generation artificial pancreas. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
Potential treatment strategy for glycogen storage disease

Potential treatment strategy for glycogen storage disease

Researchers from the Duke-NUS Graduate Medical School Singapore and Duke Medicine have identified a potential treatment strategy for an often-fatal inherited glycogen storage disease. [More]
Presence of tophi in people with gout can increase risk of developing cardiovascular disease

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

The presence of tophi - crystal deposits of uric acid found on the surface of the joints or in the skin and cartilage - in people with gout can increase their risk of developing cardiovascular disease, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco. [More]
Researchers develop more accurate method of imprinting proteins

Researchers develop more accurate method of imprinting proteins

It will be increasingly difficult for protein molecules to remain anonymous, and increasingly easy for doctors and patients to detect the early stages of latent diseases. Researchers at the Institute of Physical Chemistry of the Polish Academy of Sciences in Warsaw and the University of North Texas in Denton have perfected a method of producing thin detecting films that are able to recognize specific proteins. [More]
Promising drug candidate for chronic intractable itch

Promising drug candidate for chronic intractable itch

If you have an itch, you have to scratch it. But that’s a problem for people with a condition called “chronic intractable itch,” where that itchy sensation never goes away—a difficult-to-treat condition closely associated with dialysis and renal failure. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. [More]
Advertisement